Clesrovimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Clesrovimab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
5
Registered trials
7
Result records
20
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Clesrovimab can convert its Monoclonal antibody profile and RSV F protein biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Clesrovimab (query alias: clesrovimab) |
|---|---|
| Modality / target | Monoclonal antibody; RSV F protein; Respiratory syncytial virus F protein inhibitors |
| Highest global status | Approved |
| Originator | Merck Sharp & Dohme Corp. |
| Active developers | Merck Sharp & Dohme Corp., Merck Sharp & Dohme LLC, Merck Sharp & Dohme BV |
The MCP disease footprint includes Lower Respiratory Tract Infections, Respiratory Syncytial Virus Infections. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT04938830 | Phase 3 | Completed | 1003 | Number of Participants With Solicited Injection-site Adverse Events (AEs) in RSV Season 1 |
| NCT04767373 | Phase 2/3 | Completed | 3632 | RSV Season 1: Number of Participants With Respiratory Syncytial Virus (RSV)-Associated Medically Attended Lower Respiratory Infection (MALRI) |
| NCT04086472 | Phase 2 | Completed | 80 | Area Under the Viral Load-time Curve (VL-AUC) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab- Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease
Phase 3; n=1003; evaluation: not stated. Reported fields: Injection site erythema = 31 Participants ; -; -
Clesrovimab for Prevention of RSV Disease in Healthy Infants
Phase 2/3; n=3614; evaluation: Positive. Reported fields: RSV-associated medically attended lower respiratory infection: efficacy = 60.4(95.0% CI, 44.1 - 71.9), P-Value = <0.001; RSV-associated medically attended lower respiratory infection: efficacy = 60.4(95.0% CI, 44.1 - 71.9), P-Value = <0.001
A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants
Phase 2/3; n=3632; evaluation: not stated. Reported fields: RSV Season 1: Number of Participants With Respiratory Syncytial Virus (RSV)-Associated Medically Attended Lower Respiratory Infection (MALRI) = 60 Participants ; RSV Season 1: Number of Participants With Respiratory Syncytial Virus (RSV)-Associated Medically Attended Lower Respiratory Infection (MALRI): Efficacy estimate = 60.4(95% CI, 44.1 - 71.9), P-Value = <0.001; RSV Season 1: Number of Participants With Respiratory Syncytial Virus (RSV)-Associated Medically Attended Lower Respiratory Infection (MALRI): Efficacy estimate = 60.4(95% CI, 44.1 - 71.9), P-Value = <0.001
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Clesrovimab addresses Lower Respiratory Tract Infections, Respiratory Syncytial Virus Infections. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 20 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: RSV F protein records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-02-08 | 康泰生物：终止与阿斯利康的28亿元合资项目 | Discovery | US$400.0M stated total |
| 2025-04-28 | Dr. Reddy’s and Sanofi Healthcare India Private Limited expand partnership to launch Beyfortus® (nirsevimab), a novel drug for preventing Respiratory Syncytial Virus in India | Approved | Financial terms not disclosed |
| 2025-01-23 | SK Bioscience and Sanofi Partner to Distribute RSV and Hepatitis A Vaccines in Korea | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Anti-human RSV f protein antibodies for use in treatment or prophylaxis”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
